Cardiol Therapeutics Granted Orphan Drug Designation for its Lead Drug Candidate for the Treatment of Pericarditis

Designation Based on Pre-Clinical Data and Initial Clinical Data from the Company’s…

Cardiol Therapeutics Announces Massachusetts General Hospital, Largest Teaching Hospital of Harvard Medical School, as the 8th Major Medical Centre Participating in MAvERIC-Pilot

MAvERIC-Pilot is a Phase II Study in Recurrent Pericarditis and is Anticipated…

ADDING MULTIMEDIA MyMD Pharmaceuticals® to Present Data on Oral TNF-a Inhibitor MYMD-1® at the British Society for Immunology (BSI) Congress 2022

– Preclinical and early clinical studies of MYMD-1®, an oral, small-molecule, selective…

Longboard Pharmaceuticals to Present at Guggenheim’s Healthcare Talks 4th Annual Immunology and Neurology Day

LA JOLLA, Calif., November 08, 2022–(BUSINESS WIRE)–Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage…